Dupixent Lawsuit for T-Cell Lymphoma

June 2026 Update: Dupixent CTCL Lawsuits Centralized in New Jersey MDL

The Dupixent lymphoma lawsuits are now centralized in federal court. On June 4, 2026, the JPML created MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, and transferred the federal cases to the District of New Jersey before Judge Zahid N. Quraishi.

The MDL is focused on claims that Dupixent caused patients to develop CTCL or accelerated preexisting CTCL. The JPML order also recognized that plaintiffs allege common questions involving the science, what the defendants knew, when they should have known it, and whether they provided adequate warnings.

This is not a class action. In a class action, one or a few plaintiffs represent an entire group, and the result usually applies to everyone in the class unless they opt out. An MDL works differently. Each plaintiff keeps an individual lawsuit, with individual medical history, injury severity, damages, and settlement value. The cases are grouped together for coordinated discovery, expert challenges, motions, and pretrial rulings.

The MDL structure is usually the best path for plaintiffs with serious injuries because it allows coordinated discovery against the defendants while preserving individual damages. A patient with advanced CTCL, chemotherapy, stem cell transplant, or wrongful death has a very different case than someone with a shorter and less severe disease course.

Who May Qualify for a Dupixent Lawsuit?

Our attorneys are reviewing cases from patients who received Dupixent and were later diagnosed with T-cell lymphoma. You do not need to know whether Dupixent caused the lymphoma before calling. The first step is a medical record review, including dermatology notes, biopsy reports, pathology, oncology records, Dupixent prescription history, and treatment timeline.

You may qualify if you were prescribed Dupixent for eczema, asthma, chronic rhinosinusitis, eosinophilic esophagitis, prurigo nodularis, COPD, bullous pemphigoid, allergic fungal rhinosinusitis, or another approved condition and were later diagnosed with a T-cell lymphoma.

Not every Dupixent patient with lymphoma will qualify. But if you received Dupixent injections and were later diagnosed with any form of T-cell lymphoma, your case deserves careful review.

Who Probably Does Not Have a Strong Dupixent Lawsuit?

A case is usually weaker if the patient took Dupixent but was never diagnosed with CTCL, PTCL, mycosis fungoides, Sézary syndrome, or another T-cell lymphoma. A temporary rash, eye irritation, conjunctivitis, ordinary eczema flare, or short-term side effect is not the injury our lawyers are focused on for this litigation.

A case may also be difficult if the CTCL diagnosis clearly predated Dupixent use, if the patient took only one or two doses with no meaningful timing connection, or if the records show no worsening, delayed diagnosis, systemic symptoms, lymph node involvement, or treatment burden after Dupixent.

That does not mean you should screen yourself out if you have a confirmed T-cell lymphoma diagnosis. It means the case needs careful review. The key records are the Dupixent timeline, dermatology notes, biopsy history, pathology reports, oncology records, and the clinical course before and after the drug.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma is a cancer of the immune system involving malignant T cells that migrate to the skin. In its early stages, CTCL often looks almost indistinguishable from eczema, psoriasis, or other chronic inflammatory skin conditions. It behaves like a wolf in sheep’s clothing, presenting as ordinary rashes, plaques, itching, or redness that flare up and fade away, giving the impression of a manageable skin disorder rather than a developing cancer.

That disguise is what makes CTCL so dangerous. The disease can hide in plain sight for years, with biopsies that come back inconclusive and symptoms that mimic benign skin problems. Like a slow-burning fire behind a wall, CTCL may continue progressing quietly until it finally reveals itself, often at a more advanced stage that is far harder to treat.

The most common forms of CTCL are mycosis fungoides and Sézary syndrome. Both are serious, life-altering conditions that often require lifelong treatment. In advanced cases, they can be fatal.

Why CTCL Gets Misdiagnosed as Eczema

One of the most troubling aspects of these cases is that early CTCL and atopic dermatitis can look nearly identical, even to experienced dermatologists.

Both conditions can present with:

• Red, inflamed patches
• Itchy, scaly skin
• Lichenification, meaning thickened and leathery skin
• Fissuring and cracking
• Symptoms that flare and fade over time

Early-stage mycosis fungoides, the most common form of CTCL, often appears as flat, scaly patches that respond partially to topical steroids, just like eczema. Biopsies can come back inconclusive. Patients and doctors may assume they are dealing with stubborn dermatitis, not a developing malignancy.

So Dupixent suppresses the visible inflammation. The redness fades. The itching improves. To the patient and prescriber, this looks like the drug is working. But if the underlying condition is CTCL rather than eczema, plaintiffs allege Dupixent may mask symptoms while the disease continues to advance beneath the surface.

By the time the true diagnosis is made, treatment options may be more limited and outcomes may be worse.

What Dupixent Lawsuits Allege

Plaintiffs in Dupixent lymphoma lawsuits are making serious allegations against Regeneron and Sanofi. These cases are built primarily on failure-to-warn claims, supported by growing scientific evidence. The gap between the evidence and the warning is wide.

The bottom line is that plaintiffs allege Regeneron and Sanofi prioritized sales of a blockbuster drug over patient safety, and that the result was unnecessary human suffering in patients whose cancer diagnosis was delayed, missed, or worsened.

Medical Evidence Being Cited in Dupixent CTCL Claims

Several studies, case series, pharmacovigilance reports, and adverse event analyses are being cited in connection with Dupixent lymphoma litigation. Observational database studies have reported higher rates of CTCL diagnoses among patients treated with dupilumab compared to similar patients who were not exposed to the drug.

Other reports describe patients treated with Dupixent for presumed eczema who initially improved, then experienced disease progression consistent with CTCL. These patterns have been discussed in dermatology journals and conferences, particularly in patients with adult-onset or treatment-resistant dermatitis.

No single study proves causation for every patient. Plaintiffs argue that the collective evidence was strong enough to require clearer warnings, screening guidance, and stop-and-investigate instructions for prescribers.

Why the Warning Matters

These lawsuits are not a push to recall Dupixent from the market. The core claim is that doctors and patients were not told what they needed to know. Failure to warn is the spine of these cases.

A manufacturer that knows or should know that a subset of patients with adult-onset or refractory dermatitis may actually harbor early CTCL has a duty to communicate that risk. The practical content of the warning is not complicated: before starting treatment in adults with atypical clinical courses or biopsy-suspicious lesions, consider lymphoma. If the disease evolves in a way that is not typical for eczema, stop and investigate. Do not keep escalating Dupixent while hoping the symptoms settle down.

Design defect is less obvious in a biologic drug case than in a mechanical device case, but plaintiffs may still argue that the risk-management design for Dupixent was defective because it lacked guardrails for a known diagnostic gray zone.

In a world where early mycosis fungoides can masquerade as eczema for years, a safer risk-management approach includes prescriber education, biopsy prompts in adult-onset disease, repeat testing when symptoms evolve atypically, and clear stop rules when the clinical course deviates from eczema norms.

Potential Dupixent Settlement Amounts

Any dollar figures at this stage are speculative. This is new litigation. The science is still being tested, defendants have not been found liable, there are no bellwether verdicts, and the litigation record that usually drives settlement negotiations is still being built. But victims and families deserve a frame of reference.

Civil lawsuits assign a dollar value to suffering. The severity of the cancer, burden of treatment, strength of causation, length of delayed diagnosis, and clarity of the manufacturer’s knowledge will shape outcomes. If the medical record shows that Dupixent played a role in accelerating or masking a lymphoma diagnosis, and if discovery confirms inadequate warnings, the exposure for defendants becomes significant. If the documentation is thin or the disease course is ambiguous, settlement values decline.

Here are early working ranges that may make sense if plaintiffs succeed on the science, warnings, and causation:

These figures are not verdict predictions. In a successful trial involving advanced lymphoma, delayed diagnosis, chemotherapy, stem cell transplant, or death, a jury verdict could be much higher. But there are no Dupixent bellwether verdicts yet, and any settlement range today remains a working estimate.

For now, the key point is that Dupixent CTCL lawsuits are not nuisance-value claims. These are cancer cases with treatment burdens that juries can understand and liability theories that may resonate if plaintiffs prove the science and warning failures.

Evidence That Can Support a Dupixent Lawsuit

Dupixent cases are record-driven. The strongest cases will have a clear timeline showing the skin condition before Dupixent, the reason Dupixent was prescribed, what happened during treatment, when symptoms changed, when lymph nodes appeared, when biopsies were done, and when lymphoma was diagnosed.

If the diagnosis is uncertain, an independent pathology review may be important. Some of these cases will turn on whether earlier biopsies should have raised concern for lymphoma before Dupixent was started or continued.

Latest Dupixent Lawsuit News and Updates

Dupixent Lawsuit FAQs

What Should You Do Next?

If you or someone you love developed cutaneous T-cell lymphoma after taking Dupixent, get the case evaluated by a lawyer who understands both the medicine and the litigation. These are not routine drug cases. They involve nuanced clinical histories, immunologic complexity, pathology, and an evolving body of science.

The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or the initial diagnosis was eczema that never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.

If a claim is viable, the next step is preserving your rights under the statute of limitations in your state. That deadline varies, but it often starts running from the time of diagnosis or from the point when a reasonable person should have connected the diagnosis to the drug. The rule depends on the state, but either way, the clock matters.

These cases are unlikely to resolve quickly. But if the science continues to strengthen and the filings continue to build, there is a path to accountability. That path starts with a diagnosis, a timeline, and a decision to act.